Compositions and methods for treating and preventing chronic pain

Patent metadata

Field	Value
Publication number	US-10857382-B2
Application number	US-201716306797-A
Country	US
Kind code	B2
Filing date	Jun 2, 2017
Priority date	Jun 3, 2016
Publication date	Dec 8, 2020
Grant date	Dec 8, 2020

Abstract

Provided herein are compositions and methods for managing and minimizing chronic pain. In particular, provided herein are systems and methods for managing and minimizing chronic pain with light therapy.

First claim

The invention claimed is:

1. A method of treating pain, comprising:
administering blue or green spectrum light to retina of a subject exhibiting pain under conditions such that said subject's pain is reduced or eliminated,
wherein the blue or green spectrum light is of a wavelength between approximately 450-570 nm, and
wherein said administering comprises contacting an eye of said subject with a material that allows light between approximately 450-570 nm to enter the retina of said subject.

2. The method of claim 1 , wherein said material is selected from the group consisting of a contact lens, eye glasses, goggles, or ski goggles.

3. The method of claim 1 , wherein said material is a material that filters polluting light of a wavelength that is not between approximately 450-570 nm.

4. The method of claim 1 , wherein said subject is contacted with a light source that emits light of a wavelength between approximately 450-570 nm.

5. The method of claim 1 , wherein said subject is exposed to broad-spectrum light.

6. The method of claim 1 , wherein said light is of a wavelength of 525 nm.

7. The method of claim 1 , wherein said light is provided by a light box.

8. The method of claim 1 , wherein said administering is administering light of 4 to 500 lux for a time period of 20 minutes to 4 hours per day.

9. The method of claim 1 , wherein said administering is performed for a time period of 3 to 10 weeks.

10. The method of claim 1 , wherein said administering is 1 hour per day for 3 days.

11. The method of claim 1 , wherein said administering is repeated after a gap in time or said administering is continuous.

12. The method of claim 1 , wherein said pain is one or more of chronic pain, neuropathic pain, or chronic myalgia.

13. The method of claim 1 , wherein said administering results in release of endogenous opioids and cannabinoids selected from endorphins, enkephalins, dynorphins, or endomorphins.

14. The method of claim 1 , wherein said administering results in a biological outcome selected from the group consisting of alteration of depolarization-induced Ca 2+ influx in neurons, alteration of gene expression, or alteration of mu-opioid receptor and cannabinoid receptor I pathways.

15. The method of claim 1 , wherein said reduction or reversal of pain persists for at least 1 week after said administering is terminated.

16. The method of claim 1 , wherein said reduction or reversal of pain persists for at least 1 month after said administering is terminated.

17. The method of claim 1 , wherein said subject is further administered an opioid or non-opioid pain relief medication, wherein a dose of said opioid or non-opioid medication is reduced from a standard dose or from a dose said subject is administered prior to said administering of light.

18. A kit or system, comprising:
a) a light box, wherein said light box is configured to emit light of approximately 450-570 nm; and
b) an opioid or non-opioid pain relief medication.

19. The kit or system of claim 18 , wherein said opioid or non-opioid pain relief medication is provided at a reduced dose.

20. The kit or system of claim 18 , wherein said opioid medication is selected from the group consisting of hydromorphone, hydrocodone, oxycodone, oxymorphone, desomorphine, diacetylmorphine (Heroin), nicomorphine, dipropanoylmorphine, diamorphine, benzylmorphine, Buprenorphine, Nalbuphine, Pentazocine, meperidine, diamorphine, and ethylmorphine), fentanyl, pethidine, Oxycodone, Oxymorphone, methadone, tramadol, Butorphanol, Levorphanol, or propoxyphene.

Assignees

• Univ Arizona

Inventors

• Ibrahim Mohab M
• Khanna Rajesh

Classifications

• G02C5/00

  Constructions of non-optical parts · CPC title

• A61N2005/0648

  the light being directed to the eyes · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61N5/0622 Primary

  Optical stimulation for exciting neural tissue · CPC title

• A61N2005/0662

  Visible light · CPC title